SLC5A2 and metabolic dysfunction-associated steatohepatitis: We also demonstrated for the first time that in this mouse model of diabetes with NASH/cirrhosis/HCC at 16 weeks, there was diffuse SGLT1 expression in the hepatic lobules and strong expression by hepatocytes in the vehicle group, while SGLT2 expression was stronger in liver tumors than in the lobules.